News

Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage…

2 years ago

Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing…

2 years ago

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare…

2 years ago

Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily…

2 years ago

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing…

2 years ago

SmileDirectClub Introduces New Retainer Manufacturing Technology

Next Generation Process Leverages Patented Laser Technology To Enhance Comfort Robust Automations Improve Manufacturing Productivity And Efficiency NASHVILLE, Tenn., Sept.…

2 years ago

Organovo Announces Postponement of Annual Meeting of Stockholders

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing…

2 years ago

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive…

2 years ago

CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing…

2 years ago

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing…

2 years ago